Home Neuromodulation for Neurogenic Bladder Management in Spinal Cord Injury
Home Neuromodulation for Neurogenic Bladder Management in Spinal Cord Injury: A Hybrid Implementation-Efficacy Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Argyrios Stampas, MD
- Phone Number: (713) 797-5938
- Email: argyrios.stampas@uth.tmc.edu
Study Contact Backup
- Name: Danira Garcia Gutierrez
- Phone Number: (713) 797-7133
- Email: Danira.GarciaGutierrez@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas Health Science Center at Houston
-
Contact:
- Argyrios Stampas, MD
- Phone Number: 713-797-5938
- Email: argyrios.stampas@uth.tmc.edu
-
Contact:
- Danira Garcia Gutierrez
- Phone Number: (713) 797-7133
- Email: Danira.GarciaGutierrez@uth.tmc.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Non-progressive chronic (>1 year) SCI
- Neurologic level of injury T9 and above
- Stable over active bladder (OAB) medications (≥3 months)
- No contraindication to MRI (per MRI Safety Questionnaire)
- English or Spanish speaking
- Tolerate and be able to evoke toe flexion bilaterally with transcutaneous tibial nerve stimulation (tTNS) (self or assisted)
- Pass the tTNS competency checklist to perform or direct performance of tTNS.
Exclusion Criteria:
- Ongoing/active genitourinary oncologic diagnoses
- History of other central nervous system disorder (CNS) disorders and/or peripheral neuropathy
- Pregnancy or planning to become pregnant.
- Lower Motor Neuron bladder
- Restorative bladder surgery such as augmentation cystoplasty
- Botulinum toxin-A injections in the bladder within 6 months of trial enrolment (injection in other sites is allowed)
- Anticoagulation treatment or prophylaxis
- Advanced peripheral vascular disease (gangrene, amputation, etc.)
- History of intolerance to electrical stimulation, particularly of the leg
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Bilateral iTNS
participants will receive one active tibial nerve stimulation (TNS) device and both legs will receive active stimulation
|
The stimulation current will be gradually increased until bilateral toe flexion is achieved, then reduced to just below the motor contraction threshold.
A 20 Hz frequency and 200 µs pulse width will be applied continuously for 30 minutes, five times a week.
|
|
Active Comparator: Unilateral iTNS
participants will receive one active and one sham tibial nerve stimulation (TNS) device.
The treatment will only be delivered to the leg with the active device.
|
The stimulation current will be gradually increased until bilateral toe flexion is achieved, then reduced to just below the motor contraction threshold.
A 20 Hz frequency and 200 µs pulse width will be applied continuously for 30 minutes, five times a week.
The sham devices are designed to mimic active stimulation by initially delivering electrical current sufficient to evoke toe flexion.
However, once the current is reduced to the sensory stimulation threshold, the device automatically ramps down to 0mA while maintaining the appearance of normal functioning on the display screen.
|
|
Sham Comparator: Sham iTNS
participants will receive one one sham tibial nerve stimulation (TNS) device for bilateral use.
|
The sham devices are designed to mimic active stimulation by initially delivering electrical current sufficient to evoke toe flexion.
However, once the current is reduced to the sensory stimulation threshold, the device automatically ramps down to 0mA while maintaining the appearance of normal functioning on the display screen.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety as assessed by the number of device-related adverse events
Time Frame: From baseline to 8 weeks
|
Adverse events include lead migration and fracture, hematoma, wound infection, delayed healing, nerve injury, and autonomic dysreflexia occurrence during the procedure.
|
From baseline to 8 weeks
|
|
Accuracy as assessed by the percentage of sessions where toe flexion was achieved as recorded in subject logs.
Time Frame: From baseline to week 8
|
From baseline to week 8
|
|
|
Reliability as assessed by the average minimum current (mA) required to elicit toe flexion when testing for accuracy
Time Frame: From baseline to week 8
|
From baseline to week 8
|
|
|
Feasibility of Injectrode procedure as assessed by surveys
Time Frame: Week 8
|
Feasibility to check if reproducible training pathway can enable non-interventional physicians to competently perform Injectrode implantation and removal
|
Week 8
|
|
Physician acceptability of Injectrode device as assessed by a survey
Time Frame: Week 8
|
The acceptability survey ranges from 0 - 32, with a higher score indicating greater acceptability of the Injectrode device.
|
Week 8
|
|
Participant acceptability of Injectrode device as assessed by a survey
Time Frame: Week 8
|
The acceptability survey ranges from 0 - 25, with a higher score indicating greater acceptability of the Injectrode device.
|
Week 8
|
|
Feasibility and acceptability of the Injectrode treatment as assessed by a qualitative interview
Time Frame: Week 8
|
A semi-structured interview will be conducted with participants and providers to explore their perceptions of the Injectrode treatment.
Responses will be summarized using qualitative coding and descriptive statistics of themes.
|
Week 8
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of participants for whom bladder medication dosage reduced
Time Frame: from baseline to 8 weeks
|
from baseline to 8 weeks
|
|
Change in magnitude of dosage of medication
Time Frame: from baseline to 8 weeks
|
from baseline to 8 weeks
|
|
Change in bladder function during urodynamics as assessed by the maximum detrusor pressure (Max Pdet) in cmH20.
Time Frame: Baseline, Week 4, and Week 8
|
Baseline, Week 4, and Week 8
|
|
Change in Bladder function as assessed by the presence or absence of detrusor overactivity (DO) during urodynamics.
Time Frame: baseline, Week 4, and Week 8
|
baseline, Week 4, and Week 8
|
|
Change in bladder capacity (maximum volume in mL) during urodynamics before voiding or discomfort.
Time Frame: baseline, Week 4, and Week 8
|
baseline, Week 4, and Week 8
|
|
Change in the presence or absence of leaks during urodynamics.
Time Frame: baseline, Week 4, and Week 8
|
baseline, Week 4, and Week 8
|
|
Change in bladder sensation during urodynamics as defined by the infused volume (mL) at time of reported first sensation of filling.
Time Frame: baseline, Week 4, and Week 8
|
baseline, Week 4, and Week 8
|
|
Change in bladder sensation during urodynamics as defined by infused volume (mL) at time of reported urgency/ desire to void.
Time Frame: Baseline, Week 4, and Week 8
|
Baseline, Week 4, and Week 8
|
|
Change in bladder sensation during urodynamics as defined by the infused volume (mL) at the time of reported discomfort.
Time Frame: Baseline, Week 4, and Week 8
|
Baseline, Week 4, and Week 8
|
|
Change in detrusor compliance during urodynamics as reported by the change in bladder volume divided by the change in bladder pressure.
Time Frame: baseline, Week 4, and Week 8
|
baseline, Week 4, and Week 8
|
|
Change in the number of incontinence episodes as self-reported in the bladder diary.
Time Frame: Baseline, Week 4, and Week 8
|
Baseline, Week 4, and Week 8
|
|
Change in the frequency of catheterization as self-reported in the bladder diary.
Time Frame: Baseline, Week 4, and Week 8
|
Baseline, Week 4, and Week 8
|
|
Change in the volume of catheterization as self-reported in the bladder diary.
Time Frame: Baseline, Week 4, and Week 8
|
Baseline, Week 4, and Week 8
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Argyrios Stampas, MD, The University of Texas Health Science Center, Houston
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Neurologic Manifestations
- Central Nervous System Diseases
- Nervous System Diseases
- Wounds and Injuries
- Male Urogenital Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Trauma, Nervous System
- Urinary Bladder Diseases
- Spinal Cord Diseases
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Spinal Cord Injuries
- Urinary Bladder, Neurogenic
Other Study ID Numbers
Other Study ID Numbers
- HSC-MS-25-0582
- CDMRP-SC240085 (Registry Identifier: CDMRP-eBRAP Log Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.